ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
EBcom NL
This field is hidden when viewing the form
Consent
go to the article

go back to the homepage

  • Subscription
  • Newsletter
  • Advertise
European Biotechnology Magazine
biocom_logo
  • Latest news
  • Background
  • Opinion
  • The Mag
    • Issues
    • Special
    • Corporate publications
    • Subscribe
  • Euro Biotech Guide
  • Market Place
    • Products
    • Sponsored Publications
    • Advertise
  • Associations
  • Service
    • Newsletter
    • Contact Us
    • Editorial Team
  • Events
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ADVERTISEMENT

brain scan neon
research collaboration

TRIMTECH lands $411M Biogen deal for neurodegeneration protein degraders

Cambridge-based TRIMTECH Therapeutics has signed a research collaboration and licensing option agreement with Biogen to develop small-molecule protein degraders for neurodegenerative diseases. The deal … more ➔

london skyview
Venture Capital

Moderna creator Flagship Pioneering brings £100M AI lab to London

U.S. biotech venture creator Flagship Pioneering is investing an initial £100 million (€120 million) to establish an AI-focused company-creation lab in London, marking the first expansion of its company-building … more ➔

ADVERTISEMENT

European Union and China Cooperation Puzzle as Flags. 3d Renderi
competition

A wall around China’s labs, and a window for Europe?

Washington is moving to choke off U.S. investment in Chinese biotech. For ­European companies already building pipelines on Chinese science, the squeeze could be an opening, but a narrow one, says long-time … more ➔

Sofinnova's Crossover team
Venture Capital

Sofinnova closes €725M fund to back Europe’s late-stage biotechs

Paris-based life sciences investor Sofinnova Partners has closed its second crossover fund at €725 million ($815 million), targeting around 15 biopharma and medtech companies, primarily in Europe. … more ➔

golden bell
IPO

Windward raises $175M in IPO, adds $50M from Sanofi

Swiss biotech Windward Bio Group has priced its Nasdaq IPO at $17 per share, setting it up to raise $175 million (€158 million) from public investors and another $50 million (€45 million) through … more ➔

European Biotechnology

1 / 4
EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo
2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo
3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo
4 / 4
EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

ADVERTISEMENT

© AI
european-biotechnology-logo

NEWSLETTER


Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.


Subscribe to our free newsletter!Subscribe here

The Leadership Edit Thumbnail European Biotechnology
Appointments

Gubra’s board replaces CEO; Commit staffs its first drug program; TECregen names CMO

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: Gubra fires its CEO, Commit strengthens … more ➔

oracle crystal ball
cancer research

Orakl raises $34M to scale AI platform predicting cancer drug responses

Paris-based Orakl Oncology has raised an oversubscribed $34 million (€31 million) Series A, co-led by Swedish investor Norrsken VC and French venture firm Singular, to expand its platform combining … more ➔

ADVERTISEMENT

Sponsored Publications

1 / 3
Picture credit: Lumis International
clinical trial

Geopolitical shifts in trial outsourcing

Three developments over the past year have changed what “outsourcing” a clinical trial actually means. New U.S. tariffs on patented pharmaceuticals, a revised Chinese trial standard, and faster … more ➔

2 / 3
International companies have put Austria on the map. Picture: Paul Bauer
Innovation Hub

Austria builds life sciences momentum

Austria continues to strengthen its position as one of Europe’s most dynamic life ­sciences locations. New infrastructure, a coordinated national cluster landscape and ­targeted funding initiatives … more ➔

3 / 3
Photo credit: Richter BioLogics
CDMO

CDMO: How to find a reliable partner

Every biopharmaceutical company reaches the same crossroads when ­selecting a contract development and manufacturing (CDMO) partner. The temptation is to optimize for the lowest quote or the shortest … more ➔

APPOINTMENTS

all appointments

eb.com_Jeff_Abbey_Spica_Therapeutics_CEOSpica Therapeutics
Spica Therapeutics

New CEO for the next level

The Belgian biotech company Spica Therapeutics, specialist for Macrophages biology, appointed Jeff Abbey as new Chief Executive Officer …
more ➔

EB.com_Qiagen_CEO_Jonathan_PrattQiagen
Qiagen

New CEO took over the reins

At the beginning of September, Jonathan M. Pratt succeeded Thierry Bernard as CEO of Qiagen N.V. Bernard had led the biotech pioneer …
more ➔

Samanta CimitanLonza Group
CDMO

Samanta Cimitan to (re)join Lonza from Celonic

Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee …
more ➔

eb.com_Teresa Nunes CMO_EpilepsyGTXEpilepsyGTX
EpilepsyGTX

Clinical Development Expert has started

London-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s …
more ➔

schizophrenia
fundraising

Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2

Neurosterix, a spinout of Swiss biotech Addex Therapeutics, has raised $105 million (about €94 million) to advance its lead schizophrenia drug into Phase 2 clinical development. The Boston- and Geneva-based … more ➔

ADVERTISEMENT

Credit: Davey Gravy via Unsplash+
small molecule

Lakefront abandons Galapagos-developed TYK2 inhibitor after unsuccessful partnering efforts

Belgian biotech Lakefront Biotherapeutics, formerly Galapagos, has discontinued its oral TYK2 inhibitor GLPG3667 after analyzing the drug’s competitive landscape and holding talks with potential partners. … more ➔

Jim Scibetta
fundraising

VectorY secures €74.5M to advance ALS gene therapy trial

Amsterdam-based VectorY Therapeutics has secured €74.5 million ($83.5 million) in new financing to advance its lead gene therapy candidate for amyotrophic lateral sclerosis (ALS) and expand its pipeline … more ➔

All news
newsletter_link

EVENT


PharmaLab2025_event_lsiting_ohne-EB
November 23 - November 25in Darmstadt

PharmaLab Congress and Exhibition 2026 at a new venue

The event for all pharmaceutical laboratory sectors will continue its success story for the 14th time on 23-25 November 2026 - now at a new venue in Darmstadt (near Frankfurt Airport): the darmstadtium, a modern conference centre with state-of-the-art and sustainable technical facilities. ➔

Knowbio GmbH
  • Link to LinkedIn
  • Link to Instagram
  • Contact
  • Imprint
  • Privacy policy
Scroll to top Scroll to top Scroll to top